- ongoing, recruitingTherapeutic use (Phase IV)
Phase IV multicenter immunogenicity and safety study of the Seqirus licensed zoonotic influenza vaccine (H5N8) in adults immunized with an H5N1/MF59 influenza vaccine, approximately 20 years before the trial, compared to H5 naive adult participants.
This study is looking at a new bird flu vaccine (H5N8) in adults. We want to see how well it helps your body fight off the virus, especially if you had a similar bird flu vaccine (H5N1) many years ago, compared to those who haven't had a bird flu vaccine before.
Italy · Belgium - active not recruitingPHASE4
Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart
This study is looking at an H5N1 bird flu vaccine. We want to see how well it works and if it's safe when given in two doses, either 3 weeks or 8 weeks apart. This is important because bird flu is currently circulating.
Canada